For most of the past two decades, "robotic surgery" in the United States meant one platform. Intuitive Surgical's da Vinci system defined the modality, captured the lion's share of installed base, and shaped how surgical residents learn robotic technique.
That is no longer the picture. Several new platforms have crossed regulatory thresholds in the past two years, with meaningfully different design philosophies, price points, and target use cases. The OR landscape in 2026 is more competitive — and more confusing — than it has been in years.
Why the shift now
A few converging factors. Patents on the original generation of da Vinci technology have lapsed. Reimbursement environments have changed in ways that pressure systems to optimize OR efficiency. And artificial intelligence has begun augmenting surgical robotics in ways that go beyond what the original platforms were designed for.
The result is a wave of new entrants targeting specific niches: lower-cost systems for community hospitals, modular platforms for ambulatory surgery centers, specialized systems for orthopedics and spine, and AI-enhanced platforms designed for procedure-specific workflows.
For an industry overview, Becker's Hospital Review tracks new market entrants closely, and peer-reviewed outcomes data appears in surgical journals as well as The Lancet and JAMA Network.
The new platform categories
Rather than a single competitive landscape, the surgical robotics market in 2026 has fragmented into several distinct categories.
General-purpose laparoscopic robotic platforms. Direct competitors to da Vinci targeting general surgery, urology, gynecology, and similar workflows. Several systems are now FDA-cleared and being deployed at major academic and community hospital systems. The competitive question for these platforms is less about technical capability — most are technically comparable — and more about installed base, training infrastructure, and integration with hospital systems.
Orthopedic robotic systems. A separate, mature category focused on joint replacement (hip, knee) and spine. These systems use robotic guidance for bone preparation and implant placement, where sub-millimeter precision has demonstrable outcome benefits. Adoption has been strong in arthroplasty, with several platforms now competing.
Endoluminal and flexible robotics. A newer category — robotic platforms designed for procedures inside body cavities accessed through natural orifices rather than incisions. Bronchoscopy, colonoscopy, and similar procedures are seeing robotic platforms that combine articulation, AI navigation, and integrated imaging.
Modular and mobile systems. Designed for facilities that can't justify a dedicated robotic OR. Smaller footprint, faster setup, lower capital cost. Aimed at ambulatory surgery centers and smaller community hospitals.
What's actually different about the new platforms
Three design choices distinguish the newer entrants:
Single-port versus multi-port architectures. Several new systems are designed for single-port surgery — all instruments enter through one incision — with the goal of reducing patient morbidity and improving cosmetic outcomes. The clinical evidence is mixed; some procedures benefit, others don't, and the question is increasingly procedure-specific.
Open versus closed instrument ecosystems. Some platforms allow third-party instruments and accessories. Others lock customers into proprietary tooling. The economics of the latter — instrument costs over the lifetime of the platform — are a meaningful part of total cost of ownership and are being scrutinized by hospital procurement teams more carefully than they used to be.
AI integration depth. The most interesting differentiation is in how AI is integrated. Some platforms use AI primarily for surgeon training and credentialing — automated assessment of dexterity, evaluation of completed procedures. Others integrate AI into the surgical workflow itself — anatomic landmark identification, step-by-step procedure guidance, real-time anomaly flagging.
What the outcomes data shows
Comparative outcomes data across surgical robotic platforms is genuinely difficult to interpret, for predictable reasons.
The procedures performed differ. The surgeons performing them differ. The patient populations differ. Even within a single procedure on a single platform, surgeon experience effects dominate platform effects in most outcome measures. Studies that attempt to isolate platform effects often run into confounders that are hard to control.
The honest summary: for the major procedure categories where multiple platforms compete (urologic prostatectomy, gynecologic procedures, general surgery cholecystectomies), outcomes are broadly comparable when matched for surgeon experience. The procedure-specific platforms — orthopedic robotics, endoluminal systems — show clearer benefits in their target use cases because they're solving different problems than general laparoscopic robotics.
Cost and access pressure
Surgical robotics has historically been concentrated in academic and large community medical centers, partly for clinical training reasons and partly because of capital cost. The newer entrants are explicitly targeting this access gap.
The total cost of robotic surgery includes the capital cost of the system (millions for major platforms), instrument and consumable costs per procedure, service contracts, and the OR time investment of robotic procedures (which is often longer than equivalent open or laparoscopic procedures, especially during a surgeon's learning curve).
The push from new entrants is to bring the per-procedure cost closer to laparoscopic equivalents and to make the capital outlay feasible for smaller facilities. The CMS payment landscape, accessible through cms.gov, is also evolving in ways that affect the economics of robotic procedures.
Training and credentialing
A persistent challenge across the field is how to credential surgeons on multiple platforms. Surgical residency programs have largely standardized around the dominant platform their training hospital uses, which means a surgeon trained primarily on one system may face a learning curve transitioning to another. This is being addressed with cross-platform training programs and AI-assisted skill assessment, but the friction is real.
The American College of Surgeons and academic societies are working on credentialing frameworks that travel across platforms. The relevant guidance is publicly accessible, and the AAMC tracks training program adoption of various robotic systems.
The bigger picture: surgery is becoming more data-rich
A through-line in the new wave of platforms is data capture. Every procedure performed on a modern robotic platform generates structured data about kinematics, instrument use, time-in-task, anatomic identification, and increasingly, intraoperative video annotated by AI. This is changing how surgical quality is measured, how complications are reviewed, and how surgical training works.
The implications go beyond the OR. Documentation, billing, and post-operative communication are all affected when the procedure itself produces structured data that can flow downstream into clinical notes, op reports, and quality registries. The administrative tail of surgery is, slowly, becoming as automatable as the procedure itself.
What to watch in 2026–2027
Three trends.
Platform consolidation. Several of the new entrants are venture-backed and not yet at sustainable scale. Some will likely be acquired or merged. The competitive landscape will simplify — but not back to single-platform dominance.
International market dynamics. Several major non-US robotic platforms are growing rapidly in Asia and Europe and beginning to seek FDA clearance. The next year is likely to see the US market diversify further with international entries.
AI-driven outcome improvements. As more procedures are performed with AI-augmented platforms, the data needed to demonstrate AI-driven outcome improvements is finally accumulating. Expect the first robust comparative trials in the next 18–24 months.
The era of "robotic surgery means one company" is over. The next era is more complex, more competitive, and more focused on what specific platforms are good at — rather than a general claim that robotic is better than open or laparoscopic. For surgeons and surgical leaders, the question has shifted from "should we adopt robotics" to "which platforms for which procedures."
